Showing 1321-1330 of 1614 results for "".
- Outlook Therapeutics Receives UK Approval of Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-uk-approval-of-lytenava-for-the-treatment-of-wet-amd/2482350/Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD. Lytenava is the first and only aut
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- Vabysmo Receives CHMP Recommendation for RVO Indicationhttps://modernod.com/news/roches-vabysmo-gets-chmp-recommendation-for-rvo-indication/2482337/Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of Vabysmo (faricimab) marketing authorization to include the treatment of visual impairment caused by macular edema secondary to retin
- EMA’s CHMP Issues Negative Opinion of Syfovre for GA; Apellis to Seek Re-Examinationhttps://modernod.com/news/emas-chmp-issues-negative-opinion-for-syfovre-for-ga-apellis-to-seek-re-examination/2482336/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of Apellis’s intravitreal pegcetacoplan for the treatment of geographic atrophy (GA). “Although th
- Rayner Announces New Appointments to Management Boardhttps://modernod.com/news/rayner-announces-new-appointments-to-management-board/2482311/Rayner announced three new appointments to its management board. James Crutchlow has been appointed Chief Commercial Officer; Rob Nadler was named Chief Growth Officer; and Chris Willis was named Chief Marketing Officer, effective immediately. “T
- Zeiss Announces OCT Enhancements to Cirrus 6000https://modernod.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/Zeiss Medical Technology announced enhancements to the Cirrus 6000 designed to allow for a more efficient and data-driven workflow for ophthalmologists. The device is supported by the largest OCT reference database in the US market, according to Zeiss, as well a
- Quantel Medical Launches POCKET III Handheld Pachymeterhttps://modernod.com/news/quantel-medical-launches-pocket-iii-handheld-pachymeter/2482298/Quantel Medical, a division of Lumibird Medical, announced the launch of the POCKET III handheld pachymeter. With its compact design, Quantel says the POCKET III is the lightest connected handheld pachymeter on the market weighing just 60 grams. It offers a precise a
- Outlook Therapeutics Receives European Authorization for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-european-authorization-for-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd/2482296/Outlook Therapeutics has received European Commission Marketing Authorization for Lytenava (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD. Lytenava is the first and only authorized ophthalmic formulation of bevacizumab for use in tre
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als